Management With Non-Vitamin K Antagonist Oral Anticoagulants: Practical Challenges and Future Perspectives

Join an expert panel as they discuss contemporary data related to the use of NOACs for the prevention and treatment of thromboembolic events.

Tuesday 23 June 2015
Event Time  
12:15 - 13:45
ISTH 2015 Congress,
Metro Toronto Convention Centre,
222 Bremner Blvd, Toronto,
ON M5V 3L9, Canada


Walter Ageno, MD
Associate Professor of Medicine, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

Mark Crowther, MD, FRCPC
Professor, McMaster University, Hamilton, Ontario, Canada

Michael Spannagl, MD
Professor, Department of Hemostasis and Transfusion Medicine, University of Munich, Munich, Germany

Robert P. Giugliano, MD
Senior Investigator, TIMI Study Group; Physician, Cardiovascular Medicine, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts, United States

Target Audience

This educational activity is intended for an international audience of non-US healthcare professionals, specifically cardiologists, neurologists, internal medicine physicians, and other healthcare professionals involved in the treatment and care of patients with conditions that may require oral anticoagulant use.

Activity Overview

Join Drs Crowther, Ageno, Giugliano, and Spannagl as they discuss non-vitamin K oral antagonists (NOACs), which are now available as alternatives to warfarin and have begun to change the management of thrombus prevention and treatment in atrial fibrillation (AF), as well as how deep vein thrombosis (DVT)/pulmonary embolism (PE)are managed.



Learning Objectives

Program Agenda


Welcome and Introduction
Mark Crowther, MD FRCPC


Practical Challenges in Drug Selection: A Focus on New Agents
Robert P. Giugliano, MD


Risk Stratification and Laboratory Monitoring in Emergency Situations
Michael Spannagl, MD


Reversal Strategies for Bleeding Patients
Mark Crowther MD FRCPC


Question & Answer Session


Concluding Remarks
Walter Ageno MD


Accreditation Statement

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.5 continuing professional development credits (CPD).


Supported by an independent educational grant from